Cargando…
EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase that is of great interest in human cancer. It has been shown to have a dual nature, as it can act as a gene repressor or activator. Studies have highlighted the various roles of EZH2 in the pathophysiology of multiple myeloma (MM). It...
Autores principales: | Tremblay-LeMay, Rosemarie, Rastgoo, Nasrin, Pourabdollah, Maryam, Chang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286605/ https://www.ncbi.nlm.nih.gov/pubmed/30555699 http://dx.doi.org/10.1186/s40364-018-0148-5 |
Ejemplares similares
-
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018) -
Role of CD47 in Hematological Malignancies
por: Eladl, Entsar, et al.
Publicado: (2020) -
Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma
por: Rastgoo, Nasrin, et al.
Publicado: (2019) -
Role of epigenetics-microRNA axis in drug resistance of multiple myeloma
por: Rastgoo, Nasrin, et al.
Publicado: (2017) -
Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
por: Alzrigat, Mohammad, et al.
Publicado: (2018)